Clinical trials: Male Osteoporosis
- Condition Male Osteoporosis
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Osteoporosis
Evaluating the Pharmacokinetic Characteristics of AD-102 in Healthy Volunteers
The purpose of this study is to evaluate the pharmacokinetic characteristics of AD-102 in healthy male subjects
- Trial name
- NCT03824171
- Testing
- Raloxifene 60mg/Cholecalciferol 800IU, AD-102
- Where
- South Korea
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Healthy
Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of Single and Multiple-Doses of ATF936 and AXT914 Administered Orally in Healthy Subjects.
This is a first-in-human study and is designed to evaluate the safety, tolerability, pharmacodynamic and pharmacokinetic effects of a single and multiple-doses of ATF936 and AXT914 administered orally in healthy subjects.
- Trial name
- NCT00417261
- Testing
- ATF936, AXT914
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Novartis
Osteoporosis
A Study to Assess the Bioequivalence of Different Formulations of Risedronate in Healthy Male and Female Subjects
Randomized, double-blind, 2-treatment, 2-period, 2-sequence, crossover study, The study will consist of a screening visit, study center admission (preceding Treatment Periods 1 and 2), 2 treatment periods (4 days each), 1 washout…
- Trial name
- NCT00846196
- Testing
- risedronate DR (Phase III clinical supply), risedronate 35 mg DR (Commercial Tablet)
- Where
- 6 sites in United States
- Volunteers
- 538 people, healthy volunteers welcome
- Sponsor
- Warner Chilcott
Osteoporosis
Assess Bioequivalence of One 150 mg Risedronate Tablet Versus Two 75 mg Risedronate Tablets in Healthy Subjects
This study is a randomized, open-label, crossover study to assess the bioequivalence of 1 risedronate 150 mg tablet versus 2 risedronate 75 mg tablets administered as a single oral dose.
- Trial name
- NCT00699777
- Testing
- Risedronate
- Where
- 4 sites in United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Warner Chilcott
Postmenopausal Osteoporosis
Phase 1 Study to Compare CMAB807 Injection to Prolia® in Healthy Volunteers
CMAB807 is a human monoclonal antibody targeting the key bone resorption mediator RANKL. The drug is administered via subcutaneous injection once six months and is approved for various indications, including the treatment of…
- Trial name
- NCT03925051
- Testing
- Prolia®, CMAB807
- Where
- China
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- Shanghai Biomabs Pharmaceutical Co., Ltd.
Osteoporosis
A Study To Investigate The Metabolism And Excretion Of 14C SB-751689 Given To Healthy Males And Postmenopausal Women
This study will examine the biological fate of radioactive SB-751689 administered to healthy males and healthy postmenopausal women. Subjects will receive a single oral dose of radioactive SB-751689.
- Trial name
- NCT00499928
- Testing
- SB-751689
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Osteoporosis
HDDO-1614 Bio Equivalence Study
A randomized, open-label, single-dose, crossover study
- Trial name
- NCT03382314
- Testing
- HDDO-1614, Bazedoxifene / Cholecalciferol
- Where
- South Korea
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Hyundai Pharmaceutical Co., LTD.
Osteoporosis
Safety and Tolerability of Odanacatib (0822-059)
This study will test the weighted average inhibition of u-NTx/Cre (aminoterminal crosslinked telopeptide of Type 1 collagen) and AUC (0-168 hours) of Odanacatib
- Trial name
- NCT01068262
- Testing
- Odanacatib
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Hypoparathyroidism, Osteoporosis
Assess Safety and Compare PK of New Oral hPTH(1-34) Tablet Formulations vs. EBP05 Tablets and Subcutaneous Forteo
The purpose of this study is to characterize and compare the pharmacokinetics of hPTH(1 34) after treatment with modified oral formulations (EBP11, EBP11-F1, EBP11-F2, EBP11-F4, EBP11-F5 and EBP22) versus three dose levels of…
- Conditions
- Hypoparathyroidism, Osteoporosis, Fractures, Bone, Other Disease
- Trial name
- NCT05965167
- Testing
- EBP05, Forteo 0.02 mg, EBP11
- Where
- Israel
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Entera Bio Ltd.
Osteoporosis
Study of Multiple Oral Doses of Odanacatib (MK0822) in Healthy Adults (0822-002)
This study will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of once-daily multiple-dose administration of odanacatib (MK0822).
- Trial name
- NCT00769418
- Testing
- odanacatib
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Osteoporosis, Postmenopausal
A Clinical Trial to Evaluate the Safety and Pharmacokinetic
A phase 1 clinical trail to evaluate the safety and pharmacokinetic characteristic after administration of fixed-dose combination or loose combination of HUG186 in healthy adult male or menopausal female volunteers
- Trial name
- NCT03475719
- Testing
- HUG186-B and HUG186-D, HUG186
- Where
- South Korea
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Huons Co., Ltd.
Amyotrophic Lateral Sclerosis (ALS), Angina, Stable
Quest to Analyze One Thousand Humans Meditating
This study will be focused on assessing the molecular, physiological, and emotional correlates of an intensive meditation experience in the context of a retreat setting in a large 2000 plus-person cohort comprised of healthy and…
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Angina, Stable, Anxiety, Asthma
- Trial name
- QUANTUM (NCT06583395)
- Testing
- Advanced multi-component meditation practice
- Where
- United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Tobias Moeller-Bertram